InPortal

InPortal is a medical technology and biotechnology company focused on the targeted delivery of therapeutics to the central nervous system by bypassing the blood-brain barrier (BBB). The company's proprietary InPortal Delivery System utilizes a microcatheter-based approach to perform intra-arterial infusion of hyperosmolar solutions, which temporarily opens the BBB to allow high concentrations of drugs to reach brain tissue. This platform is designed to enhance the efficacy of chemotherapies, monoclonal antibodies, and other large-molecule therapeutics for treating aggressive brain cancers such as glioblastoma and CNS lymphoma. By localizing drug delivery, InPortal aims to maximize therapeutic impact while minimizing systemic toxicity. The technology is currently being evaluated in clinical settings for various neuro-oncology and cerebrovascular indications.